Non-alcoholic-Related Fatty Liver Disease (NAFLD) as a Risk Factor for Atherosclerotic Cardiovascular Disease: The Hidden Link – ASCVD Risk Factors from NAFLD
<p id="p1">Non-alcoholic fatty liver disease (NAFLD) is a significant independent risk factor for atherosclerotic cardiovascular diseases (ASCVDs). The incidence of ASCVD has increased along with the prevalence of NAFLD. ASCVD events are common and a leading cause of mortality in patients with NAFLD...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1199749 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">Non-alcoholic fatty liver disease (NAFLD) is a significant independent risk factor for atherosclerotic cardiovascular diseases (ASCVDs). The incidence of ASCVD has increased along with the prevalence of NAFLD. ASCVD events are common and a leading cause of mortality in patients with NAFLD. Numerous observational, cohort, and genetic studies have confirmed an association between NAFLD and ASCVD. Most studies have indicated that NAFLD markedly increases the risk of atherosclerosis and ASCVD. Furthermore, the underlying pro-atherosclerotic mechanisms of NAFLD have been elucidated, with shared pathophysiological factors including insulin resistance, systemic inflammation, and dyslipidemia from NAFLD exacerbating atherosclerosis. Recently, NAFLD has emerged as a risk factor for ASCVD, garnering interest as a potential therapeutic target. This review seeks to elucidate mechanistic insights, present recent clinically significant research, and investigate emerging therapies, including novel anti-diabetic and lipid-lowering agents, that may ameliorate NAFLD and mitigate ASCVD risk.</p> |
|---|---|
| ISBN: | 978-1-83634-026-3 |
| DOI: | 10.5772/intechopen.1009971 |